文献速递胸部技术与安全CT

基于非侵入性CT的多区域影像组学预测非小细胞肺癌术前新辅助化疗免疫治疗后病理完全缓解

Non-invasive CT based multiregional radiomics for predicting pathologic complete response to preoperative neoadjuvant chemoimmunotherapy in non-small cell lung cancer.
PubMed 文献 · Eur J Radiol · 2025-05-19

纳入216例接受新辅助化疗免疫治疗后手术的非小细胞肺癌患者,从治疗前基线CT提取瘤内及瘤周3 mm、6 mm区域特征建立5种影像组学模型。瘤内联合瘤周3 mm模型为独立预测因子(P<0.001),验证队列AUC为0.75,在N2期和抗PD-1/PD-L1亚组AUC分别为0.829和0.833。

要点

  • 治疗前CT瘤内联合瘤周3 mm影像组学模型预测病理完全缓解,验证队列AUC为0.75。
  • 该模型在N2期和抗PD-1/PD-L1亚组AUC分别为0.829和0.833。
  • 多因素分析仅瘤内联合瘤周3 mm影像组学特征为病理完全缓解独立预测因子(P<0.001)。

核心结论

  • 多区域影像组学模型在预测非小细胞肺癌新辅助化疗免疫治疗后病理完全缓解方面显示出潜力,并在不同特定亚组中表现出良好预测性能。

研究设计与样本

  • 研究纳入216例接受新辅助化疗免疫治疗后手术的非小细胞肺癌患者,随机分为训练集和验证集,从治疗前基线CT提取瘤内及瘤周3 mm、6 mm区域特征,用机器学习算法建立5种影像组学模型。

诊断标准与关键数值

  • 瘤内联合瘤周3 mm多区域影像组学模型预测病理完全缓解,验证队列AUC为0.75。

临床应用与阅片要点

  • 作者认为该模型可能帮助临床医生识别适合新辅助化疗免疫治疗的候选患者,并促进精准治疗的进展。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: This study aims to develop and validate a multiregional radiomics model to predict pathological complete response (pCR) to neoadjuvant chemoimmunotherapy in non-small cell lung cancer (NSCLC), and further evaluate the performance of the model in different specific subgroups (N2 stage and anti-PD-1/PD-L1).

MATERIALS AND METHODS: 216 patients with NSCLC who underwent neoadjuvant chemoimmunotherapy followed by surgical intervention were included and assigned to training and validation sets randomly. From pre-treatment baseline CT, one intratumoral (T) and two peritumoral regions (P3: 0-3 mm; P6: 0-6 mm) were extracted. Five radiomics models were developed using machine learning algorithms to predict pCR, utilizing selected features from intratumoral (T), peritumoral (P3, P6), and combined intra- and peritumoral regions (T + P3, T + P6). Additionally, the predictive efficacy of the optimal model was specifically assessed for patients in the N2 stage and anti-PD-1/PD-L1 subgroups.

RESULTS: A total of 51.4 % (111/216) of patients exhibited pCR following neoadjuvant chemoimmunotherapy. Multivariable analysis identified that only the T + P3 radiomics signature served as independent predictor of pCR (P < 0.001). The multiregional radiomics model (T + P3) exhibited superior predictive performance for pCR, achieving an area under the curve (AUC) of 0.75 in the validation cohort. Furthermore, this multiregional model maintained robust predictive accuracy in both N2 stage and anti-PD-1/PD-L1 subgroups, with an AUC of 0.829 and 0.833, respectively.

CONCLUSION: The proposed multiregional radiomics model showed potential in predicting pCR in NSCLC after neoadjuvant chemoimmunotherapy, and demonstrated good predictive performance in different specific subgroups. This capability may assist clinicians in identifying suitable candidates for neoadjuvant chemoimmunotherapy and promote the advancement in precision therapy.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Fan S, Xie J, Zheng S, et al. Non-invasive CT based multiregional radiomics for predicting pathologic complete response to preoperative neoadjuvant chemoimmunotherapy in non-small cell lung cancer. Eur J Radiol. 2025. PMID: 40398002. doi:10.1016/j.ejrad.2025.112171

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。